Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
Substantially Bolstered Balance Sheet Through a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025, Based on Initial $80 Million Tranche Received Fourth U.S. Patent Directed to Use of …